223 related articles for article (PubMed ID: 16804825)
21. A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy.
Christensen TL; Poulsen PB; Holmstrom S; Walt JG; Vetrugno M
Curr Med Res Opin; 2005 Nov; 21(11):1837-44. PubMed ID: 16307705
[TBL] [Abstract][Full Text] [Related]
22. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
24. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
Varma R; Hwang LJ; Grunden JW; Bean GW
Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
[TBL] [Abstract][Full Text] [Related]
25. Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema.
Wendel C; Zakrzewski H; Carleton B; Etminan M; Mikelberg FS
J Glaucoma; 2018 May; 27(5):402-406. PubMed ID: 29505438
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
27. Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.
Steinhäuser SL
Optometry; 2006 Apr; 77(4):177-9. PubMed ID: 16567279
[TBL] [Abstract][Full Text] [Related]
28. Hypertrichosis of the eyelashes caused by bimatoprost.
Tosti A; Pazzaglia M; Voudouris S; Tosti G
J Am Acad Dermatol; 2004 Nov; 51(5 Suppl):S149-50. PubMed ID: 15577756
[TBL] [Abstract][Full Text] [Related]
29. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2444-50. PubMed ID: 15980234
[TBL] [Abstract][Full Text] [Related]
30. Latanoprost-associated cystoid macular edema.
Callanan D; Fellman RL; Savage JA
Am J Ophthalmol; 1998 Jul; 126(1):134-5. PubMed ID: 9683162
[TBL] [Abstract][Full Text] [Related]
31. Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade.
Jäger M; Jonas JB
Eur J Ophthalmol; 2003 Mar; 13(2):221-2. PubMed ID: 12696646
[TBL] [Abstract][Full Text] [Related]
32. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery.
Camras CB; Toris CB; Sjoquist B; Milleson M; Thorngren JO; Hejkal TW; Patel N; Barnett EM; Smolyak R; Hasan SF; Hellman C; Meza JL; Wax MB; Stjernschantz J
Ophthalmology; 2004 Dec; 111(12):2193-8. PubMed ID: 15582073
[TBL] [Abstract][Full Text] [Related]
33. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma.
How AC; Kumar RS; Chen YM; Su DH; Gao H; Oen FT; Ho CL; Seah SK; Aung T
Br J Ophthalmol; 2009 Jun; 93(6):782-6. PubMed ID: 19336424
[TBL] [Abstract][Full Text] [Related]
34. Cystoid macular edema associated with topical echothiophate iodide.
Halperin LS; Goldman HB
Ann Ophthalmol; 1993 Dec; 25(12):457-8. PubMed ID: 8129329
[TBL] [Abstract][Full Text] [Related]
35. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes.
Wand M; Gaudio AR; Shields MB
J Cataract Refract Surg; 2001 Sep; 27(9):1397-401. PubMed ID: 11566522
[TBL] [Abstract][Full Text] [Related]
36. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension.
Arcieri ES; Pierre Filho PT; Wakamatsu TH; Costa VP
Eye (Lond); 2008 Feb; 22(2):179-83. PubMed ID: 16936646
[TBL] [Abstract][Full Text] [Related]
37. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
Trattler W; Noecker RJ; Earl ML
Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
[TBL] [Abstract][Full Text] [Related]
38. A direct correlation of the resolution of pseudophakic cystoid macular edema with acetazolamide therapy.
Tripathi RC; Fekrat S; Tripathi BJ; Ernest JT
Ann Ophthalmol; 1991 Apr; 23(4):127-9. PubMed ID: 2064253
[TBL] [Abstract][Full Text] [Related]
39. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.
Ayyala RS; Cruz DA; Margo CE; Harman LE; Pautler SE; Misch DM; Mines JA; Richards DW
Am J Ophthalmol; 1998 Oct; 126(4):602-4. PubMed ID: 9780112
[TBL] [Abstract][Full Text] [Related]
40. Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.
Crowston JG; Lindsey JD; Morris CA; Wheeler L; Medeiros FA; Weinreb RN
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4571-7. PubMed ID: 16303950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
